FDA foreign data for current fiscal year find that 68% of actionable inspections involve bulk drugs.
FDA FOREIGN INSPECTIONS: 68% REQUIRING FURTHER ACTION ARE FOR BULK DRUGS during the current fiscal year, according to data compiled by FDA's international programs staff. About 70% of the inspections performed abroad during this time frame were on bulk facilities and 30% on finished dosage form plants. The inspections, when classified by degree of seriousness of the findings, show a proportional breakdown: 68% of the total number of inspections given FDA's "official action indicated" (OAI) designation -- meaning that follow-up enforcement action is warranted -- were for bulk drugs compared to 32% for finished drugs. Bulk drug inspections comprised 66% of those classified as "voluntary action indicated" (VAI) compared to 34% for dosage forms.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth